Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(N Engl J Med [JO] AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
656 results
  • Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. [Journal Article]
    N Engl J Med. 2021 Jul 21 [Online ahead of print]Lopez Bernal J, Andrews N, … Ramsay M
  • CONCLUSIONS: Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses. Absolute differences in vaccine effectiveness were more marked after the receipt of the first dose. This finding would support efforts to maximize vaccine uptake with two doses among vulnerable populations. (Funded by Public Health England.).
  • Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. [Journal Article]
    N Engl J Med. 2021 Jul 14 [Online ahead of print]Dougan M, Nirula A, … BLAZE-1 Investigators
  • CONCLUSIONS: Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19-related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).
  • Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. [Journal Article]
    N Engl J Med. 2021 Jul 07 [Online ahead of print]Jara A, Undurraga EA, … Araos R
  • CONCLUSIONS: Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigación y Desarrollo and others.).
  • Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. [Journal Article]
    N Engl J Med. 2021 07 22; 385(4):320-329.Thompson MG, Burgess JL, … Gaglani M
  • CONCLUSIONS: Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines attenuated the viral RNA load, risk of febrile symptoms, and duration of illness among those who had breakthrough infection despite vaccination. (Funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention.).
  • Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. [Journal Article]
    N Engl J Med. 2021 Jun 30 [Online ahead of print]Heath PT, Galiza EP, … 2019nCoV-302 Study Group
  • CONCLUSIONS: A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS-CoV-2 infection and showed high efficacy against the B.1.1.7 variant. (Funded by Novavax; EudraCT number, 2020-004123-16.).
  • SARS-CoV-2 Variants and Vaccines. [Journal Article]
    N Engl J Med. 2021 Jul 08; 385(2):179-186.Krause PR, Fleming TR, … Henao-Restrepo AM
  • Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.
  • Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. [Journal Article]
    N Engl J Med. 2021 Jun 16 [Online ahead of print]Guimarães PO, Quirk D, … STOP-COVID Trial Investigators
  • CONCLUSIONS: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.).
  • Treatment of Multisystem Inflammatory Syndrome in Children. [Multicenter Study]
    N Engl J Med. 2021 07 01; 385(1):11-22.McArdle AJ, Vito O, … BATS Consortium
  • CONCLUSIONS: We found no evidence that recovery from MIS-C differed after primary treatment with IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone, although significant differences may emerge as more data accrue. (Funded by the European Union's Horizon 2020 Program and others; BATS ISRCTN number, ISRCTN69546370.).
New Search Next